A Phase 3, Single-arm, Multicenter Study to Evaluate the Efficacy and Safety of UGN-104, a Novel Formulation of UGN-101, for the Treatment of Patients With Low-grade Upper Tract Urothelial Cancer (LG-UTUC)

17129UT002-NCT06774131OpenA Phase 3, Single-arm, Multicenter Study to Evaluate the Efficacy and Safety of UGN-104, a Novel Formulation of UGN-101, for the Treatment of Patients With Low-grade Upper Tract Urothelial Cancer (LG-UTUC)UT002NCT06774131IndustrialAdultTreatmentIIIGlobalKidneyStamatakis, LambrosGenito-urinaryOncology GroupMHRI Washington Cancer Institute16158Win PhyuWin Phyuwin.phyu@medstar.net2026.1.0 Build 16 <a href="https://advarra.com" target="_blank">© 2026 Advarra, Inc.</a>